美国FDA药物批准数据库：lib.hebust.edu/ywyfzsk/zsk/nda/default.htm | ||
代码 | 专利用途码释义 | |
*PED | Pediatric exclusivity [儿科专用药] | |
DP | Drug Product claim [药物产品保护] | |
DS | Drug Substance claim [药物物质保护] | |
DS DP | Drug Substance claim & Drug Product claim [药物物质保护和产品保护] | |
U1 | PREVENTION OF PREGNANCY [避孕] | |
U10 | DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALAMIC MALFUNCTIONS OR LESIONS IN HUMANS[人类下丘脑机能障碍或病变识别诊断方法] | |
U100 | METHOD OF TREATING OCULAR INFLAMMATION [眼部感染治疗方法] | |
U101 | ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED | |
U102 | METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN | |
U103 | TREATMENT OF OCULAR HYPERTENSION [治疗眼压高] | |
U104 | TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE | |
U105 | EMESIS [呕吐] | |
U106 | TREATMENT OF EPILEPSY [治疗癫痫症] | |
U107 | TREATMENT OF HYPERTENSION AND ANGINA PECTORIS [治疗高血压和心绞痛] | |
U108 | SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS AND MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS | |
U109 | USE AS AN ADJUNCT TO DIET IN THE TREATMENT OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SATURATED FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE | |
U11 | TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS | |
U110 | USE AS A RETRIEVABLE PESSARY | |
U111 | DIABETES [糖尿病] | |
U112 | CONTRACEPTION [避孕方法] | |
U113 | METHOD OF CONDUCTING A RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE | |
U114 | USE FOR INHIBITING BONE RESORPTION[用于抑制骨吸收] | |
U115 | USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS | |
U116 | METHOD OF MYOCARDIAL IMAGING | |
U117 | TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES | |
U118 | METHOD OF LOWERING BLOOD SUGAR LEVEL | |
U119 | TREATMENT OF NASAL HYPERSECRETION | |
U12 | METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION | |
U120 | CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES | |
U121 | METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS | |
U122 | A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS | |
U123 | METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS | |
U124 | TREATMENT OF ACNE [痤疮的治疗] | |
U125 | TREATING NEUROGENERATIVE DISEASES | |
U126 | TREATMENT OF GASTRITIS [胃炎的治疗] | |
U127 | METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE [产生神经肌肉阻滞的方法] | |
U128 | METHODS FOR TREATMENT OF TUMORS [肿瘤的治疗方法] | |
U129 | METHOD TO DESTROY OR IMPAIR TARGET CELLS [消灭或减少靶细胞的方法] | |
U13 | A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT | |
U130 | MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS | |
U131 | PHOTODAMAGED SKIN | |
U132 | INHIBITING HIV PROTEASE | |
U133 | MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET | |
U134 | TREATMENT OF ACNE VULGARIS | |
U135 | ANTITUMOR AGENT | |
U136 | PROCESS FOR WASTE NITROGEN REMOVAL | |
U137 | METHOD OF TREATING BACTERIAL VAGINOSIS | |
U138 | TREATMENT OF ALLERGIC RHINITIS | |
U139 | TREATMENT OF ALLERGIC REACTIONS | |
U14 | ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES | |
U140 | USE OF NORVIR TO INHIBIT HIV PROTESASE OR TO INHIBIT AN HIV INFECTION | |
U141 | TREATMENT OF ULCERATIVE COLITIS | |
U142 | METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE | |
U143 | BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING | |
U144 | BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS | |
U145 | BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS | |
U146 | METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS | |
U147 | DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2 | |
U148 | DEVICE FOR COLLECTING A BREATH SAMPLE | |
U149 | METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES | |
U15 | METHOD OF LOWERING INTRAOCULAR PRESSURE | |
U150 | METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE | |
U151 | RELIEF OF SYMPTOMS OF THE COMMON COLD | |
U152 | METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER | |
U153 | TREATMENT OF INITIAL EPISODE GENITAL HERPES | |
U154 | METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER | |
U155 | TREATMENT OF ERECTILE DYSFUNCTION | |
U156 | METHOD OF PROVIDING ANESTHESIA | |
U157 | TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY | |
U158 | ANGINA[心绞痛] | |
U159 | TREATMENT OF INTERSTITIAL CYSTITIS | |
U16 | USE IN LUNG SCANNING PROCEDURES | |
U160 | TREATMENT OF BACTERIAL INFECTIOUS DISEASE | |
U161 | METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT | |
U162 | METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA | |
U163 | METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS | |
U164 | METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS | |
U165 | TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA | |
U166 | TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER | |
U167 | METHOD FOR TREATING HIV-1 INFECTION | |
U168 | METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA | |
U169 | METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING | |
U17 | TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS | |
U170 | METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT | |
U171 | METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT | |
U172 | TREATMENT OF GENITAL WARTS | |
U173 | ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES | |
U174 | USE AS AN ANTIHISTAMINE AGENT | |
U175 | METHOD OF TREATING MALIGNANT TUMORS | |
U176 | METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSIS | |
U177 | FUNGICIDE | |
U178 | FACILITATED ADHERENCE OF AGENTS TO SKIN | |
U179 | ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT | |
U18 | METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS | |
U180 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION | |
U181 | PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST | |
U182 | USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION | |
U183 | TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION | |
U184 | TREATING ALLERGIC EYE DISEASES IN HUMANS | |
U185 | METHOD OF TREATING HYPERTENSION[高血压治疗方法] | |
U186 | METHOD FOR TREATING GI DISORDERS CAUSED BY H. PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT | |
U187 | THERAPEUTIC TREATMENT OF CALCIFIC TUMORS | |
U188 | TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER | |
U189 | ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE | |
U19 | TREATMENT OF INFLAMMATION[炎症的治疗] | |
U190 | USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR | |
U191 | METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN | |
U192 | USE IN TREATING ALLERGIC REACTIONS 矜持什么意思 | |
U193 | PSORIASIS[牛皮鲜] | |
U194 | TREATING AGINA PECTORIS AND HIGH BLOOD PRESSURE | |
U195 | METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON | |
U196 | TREATMENT OF METASTIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS | |
U197 | USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER | |
U198 | TREATMENT METASTATIC CARCINOMA OF OVARY AFTER FIRST-LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI’S SARCOMA | |
U199 | METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT | |
U2 | TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA | |
U20 | A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT | |
U200 | METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT | |
U201 | METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT | |
U202 | METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS | |
U203 | TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY | |
U204 | USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI’S SARCOMA | |
U205 | METHOD FOR TREATING HEARTBURN | |
U206 | METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENOUS LH, IN IN VITRO FERTILIZATION | |
U207 | USE AS NASAL SPRAY | |
U208 | VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION | |
U209 | VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION | |
U21 | TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS | |
U210 | METHOD OF TREATING CONGESTIVE HEART FAILURE | |
U211 | USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION | |
U212 | METHOD OF TREATMENT OF PARKINSON’S DISEASE | |
U213 | METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA | |
U214 | USE AS A BLOOD GLUCOSE-LOWERING AGENT | |
U215 | TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS | |
U216 | TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C, BY ADMINISTERING AN AGONIST OF LR-RH AND FLUTAMIDE | |
U217 | METHOD OF PRODUCING ANESTHESIA | |
U218 | METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT | |
U219 | TREATMENT OF PARKISON’S DISEASE | |
U22 | METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS | |
U220 | METHOD OF DIAGNOSIS[诊断方法] | |
U221 | SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION | |
U222 | METHOD OF TREATING PAGET'S DISEASE USING ACTONEL | |
U223 | TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS | |
U224 | CONTROLLING INTRAOCULAR PRESSURE | |
U225 | METHOD FOR DELIVERY | |
U226 | METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE | |
U227 | NASAL ADMINISTRATION | |
U228 | ASTHMA | |
U229 | CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE) | |
U23 | METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE | |
U230 | PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS | |
U231 | USE IN PARKINSON’S DISEASE | |
U232 | METHOD OF TREATING MIGRAINE | |
U233 | DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE | |
U234 | METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS | |
U235 | METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE | |
U236 | TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3 MG/DAY | |
U237 | METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS | |
U238 | IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST | |
U239 | TREATING OR CONTROLLING OCULAR INFLAMMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO THE AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID | |
U24 | METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST | |
U240 | TREATMENT OF ACUTE MIGRAINE ATTACKS | |
U241 | FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS | |
U242 | USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION | |
U243 | TOPICAL ADMINISTRATION | |
U244 | PLATELET AGGREGATION INHIBITORS | |
U245 | TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS | |
U246 | PHOSPHATE BINDING | |
U247 | TREATMENT OF RHEUMATOID ARTHRITIS | |
U248 | TREATMENT OF HIV[HIV的治疗] | |
U249 | METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE | |
U25 | REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS | |
U250 | TREATMENT OF HEPATITIS B INFECTION | |
U251 | USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES | |
U252 | METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER’S DISEASE | |
U253 | ORAL TRANSMUCOSAL USE | |
U254 | USE OF AGGRASTAT IN COMBINATION WITH HEPARIN | |
U255 | IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY | |
U256 | TREATMENT OF HIV INFECITON IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS | |
U257 | TREATMENT OF HIV INFECTION | |
U258 | TREATMENT OF NEURODEGENERATIVE DISEASES | |
U259 | TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION OF DRUG SUBSTANCE | |
U26 | REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF | |
U260 | REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION | |
U261 | TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE | |
U262 | TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE | |
U263 | METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN. | |
U264 | METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN | |
U265 | USE AS A LAXATIVE[用作泻药] | |
U266 | RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS | |
U267 | PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE | |
U268 | ACROMEGALY | |
U269 | EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS | |
U27 | DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF | |
U270 | METHOD FOR IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT | |
U271 | METHOD OF TREATING TUMORS[治疗肿瘤的方法] | |
U272 | METHOD OF TREATING CARCINOMA[治疗癌症的方法] | |
U273 | CUTANEOUS T-CELL LYMPHOMA | |
U274 | ZANAMIVIR FOR INHALATION | |
U275 | METHOD OF USE OF THE DRUG SUBSTANCE | |
U276 | METHOD OF USE OF LEVOBUPIVACAINE | |
U277 | NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING) | |
U278 | METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT | |
U279 | METHOD OF USE OF THE APPROVED PRODUCT | |
U28 | CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY | |
U280 | TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE | |
U281 | ANTIMYCOTIC USES, SPECIFICALLY, TREATMENT OF ONYCHOMYCOSIS | |
U282 | METHOD OF TREATING BACTERIAL INFECTIONS | |
U283 | METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE | |
U284 | MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS | |
U285 | DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA | |
U286 | DEPRESSION | |
U287 | TREATMENT OR PREVENTION OF OSTEOPOROSIS | |
U288 | THERAPY OF INFLUENZA | |
U289 | TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP | |
U29 | CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY | |
U290 | INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) | |
U291 | INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN | |
U292 | INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE | |
U293 | INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID | |
U294 | TREATMENT OF HYPERPIGMENTARY DISORDERS | |
U295 | TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS | |
U296 | TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA, NAUSEA AND FUNCTIONAL DISABILITY | |
U297 | PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS | |
U298 | METHOD OF COMBATING BACTERIA IN A PATIENT | |
U299 | TREATMENT OF ADENOMATOUS POLYPS | |
U3 | TREATMENT OF HYPERTENSION | |
U30 | CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY | |
U300 | INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA | |
U301 | USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES | |
U302 | TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS | |
U303 | METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPORISIS, PAGET’S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS | |
U304 | A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION | |
U305 | METHODS FOR USING THE DRUG PRODUCT | |
U306 | TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY | |
U307 | CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA | |
U308 | CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA | |
U309 | TREATING SJOEGREN SYNDROME | |
U31 | INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY | |
U310 | TREATMENT OF XEROSTOMIA | |
U311 | HORMONE REPLACEMENT | |
U312 | PANIC DISORDER OBSESSIVE-COMPULSIVE DISORDER POSTTRAUMATIC STRESS DISORDER | |
U313 | TREATMENT OF CONGESTIVE HEART FAILURE | |
U314 | METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY | |
U315 | METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT | |
U316 | METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER | |
U317 | METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE | |
U318 | TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE | |
U319 | TREATMENT OF MICROBIAL INFECTIONS | |
U32 | PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN | |
U320 | INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA | |
U321 | REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS | |
U322 | TREATMENT OF ALZHEIMER’S DEMENTIA | |
U323 | USE AS A BILE ACID SEQUESTRANT | |
U324 | METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE | |
U325 | METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING "BIPOLAR DISORDER NOS" EMPLOYING OLANZAPINE | |
U326 | METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER | |
U327 | METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITIONS EMPLOYING OLANZAPINE | |
U328 | METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING "A PSYCHOTIC CONDITION" EMPLOYING AN OLANZAPINE POLYMORPH | |
U329 | USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | |
U33 | TREATING VIRAL INFECTIONS IN A MAMMAL | |
U330 | TREATMENT OF NAUSEA AND VOMITING | |
U331 | METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT | |
U332 | TREATMENT OR PREVENTION OF BRONCHOSPASM | |
U333 | METHOD OF TREATING OCULAR HYPERTENSION | |
U334 | TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR | |
U335 | USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS | 牛郎织女古诗|
U336 | DIAGNOSTIC RADIOIMAGING | |
U337 | USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI | |
U338 | METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME | |
U339 | PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN | |
U34 | TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL | |
U340 | THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN | |
U341 | METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER | |
U342 | METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER | |
U343 | REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION | |
U344 | METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR | |
U345 | RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION | |
U346 | METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS METABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR | |
U347 | METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS | |
U348 | METHOD OF USE FOR INHIBITING HIV INFECTION | |
U349 | METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION | |
U35 | TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION | |
U350 | PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR | |
U351 | INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIR | |
U352 | INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR | |
U353 | PREVENTION AND TREATMENT OF OSTEOPOROSIS | |
U354 | METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT | |
U355 | METHOD OF ASSISTING PERSON TO TRANSDERMALLY ADMIN PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING | |
U356 | DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A | |
U357 | USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE | |
U358 | DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER | |
U359 | METHOD OF USE OF VISICOL | |
U36 | METHODS OF TREATING BACTERIAL ILLNESSES | |
U360 | METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011 | |
U361 | MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY | |
U362 | USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS | |
U363 | METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATER OF THIS SNDA-011 | |
U364 | TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011 | |
U365 | METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION | |
U366 | METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION | |
U367 | TREATMENT OF CARDIOVASCULAR DISORDERS | |
U368 | HEARTBURN | |
U369 | METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE | |
U37 | METHOD OF TREATING GASTROINTESTINAL DISEASE | |
U370 | INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS | |
U371 | APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.) | |
U372 | METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO | |
U373 | GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OFGERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE | |
U374 | KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX | |
U375 | METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C | |
U376 | TREATMENT OF INFLUENZA | |
U377 | METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS | |
U378 | METHOD FOR TREATING INCONTINENCE | |
U379 | METHOD OF TREATING ONYCHROMYCOSIS | |
U38 | TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA | |
U380 | COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS | |
U381 | TREATMENT OF HYPERPHOSPHATEMIA | |
U382 | METHOD OF STABLIZING PROSTAGLANDIN | |
U383 | METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION | |
U384 | TREATMENT OF CMV RETINITIS | |
U385 | TREATMENT OF PEPTIC ULCERS | |
U386 | TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA | |
U387 | TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS | |
U388 | SMOKING CESSATION AID APPLIED TO THE SKIN | |
U389 | SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS | |
U39 | ANGINA PECTORIS | |
U390 | METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS) | |
U391 | USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER | |
U392 | TREATMENT OF PATIENTS FOR INFLAMMATION | |
U393 | MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT | |
U394 | METHOD OF USE OF ALPHAGAN | |
U395 | METHOD OF USE OF ALPHAGAN P | |
U396 | METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION | |
U397 | METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA | |
U398 | 出示的英文TREATMENT OF GENERALIZED ANXIETY DISORDER | |
U399 | IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS | |
U4 | PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS | |
U40 | METHOD OF TREATMENT OF BURNS | |
U400 | USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESP0NSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS | |
U401 | USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS | |
U402 | TREATMENT OF ACTINIC KERATOSES | |
U403 | ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES | |
U404 | TREATMENT OF ALLERGIC CONJUNCTIVITIS | |
U405 | FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME(IBS) | |
U406 | METHOD OF USE OF ATOVAQUONE AND PROGUANIL | |
U407 | METHOD OF TREATING OTOPATHY | |
U408 | FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION | |
U409 | METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE | |
U41 | METHOD OF TREATING CARDIAC ARRHYTHMIAS | |
U410 | METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER | |
U411 | METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA(WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION | |
U412 | TREATMENT OF TYPE 2 DIABETES | |
U413 | USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS | |
U414 | A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE | |
U415 | A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS | |
U416 | A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS | |
U417 | COMBINATION USE OF AD-4833 WITH A BIGUANIDE 什么是守岁 | |
U418 | A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER | |
U419 | A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE | |
U42 | ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER | |
U420 | METHOD OF TREATMENT OF TYPE II DIABETES | |
U421 | USE FOR SEDATION | |
U422 | METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER | |
U423 | METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA | |
U424 | FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS | |
U425 | METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER | |
U426 | PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION | |
U427 | METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS | |
U428 | METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE | |
U429 | METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS | |
U43 | MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA | |
U430 | METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT COMPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER | |
U431 | POSTTRAUMATIC STRESS DISORDER | |
U432 | REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION, OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE | |
U433 | USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS | |
U434 | CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS | |
U435 | A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG | |
U436 | ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS | |
U437 | METHOD OF USE EQUAL TO PROCESS OF PREPARATION | |
U438 | TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE | |
U439 | TREATMENT OF OBESITY | |
U44 | RELIEF OF NAUSEA AND VOMITING | |
U440 | METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE | |
U441 | METHOD OF TREATING MS BY ADMINISTERING COPAXONE | |
U442 | METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG | |
U443 | MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME | |
U444 | TREATMENT OF MIGRAINE | |
U445 | USE AS AN ANTIMYCOTIC AGENT | |
U446 | TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA | |
U447 | METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT | |
U448 | METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT- LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT | |
U449 | USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER | |
U45 | TREATMENT OF INFLAMMATION AND ANALGESIA | |
U450 | INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS, SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING | |
U451 | TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER | |
U452 | USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI) | |
U453 | TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS | |
U454 | METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN | |
U455 | TREATMENT OF PULMONARY HYPERTENSION WITH UT-15 | |
U456 | METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE | |
U457 | METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN | |
U458 | METHOD OF USE OF IMAGENT | |
U459 | TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER | |
U46 | TREATMENT OF PANIC DISORDER | |
U460 | METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE | |
U461 | METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE | |
U462 | SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA | |
U463 | VENOGRAPHY | |
U464 | PERIPHERAL ARTERIOGRAPHY | |
U465 | CT IMAGING OF THE HEAD | |
U466 | TREATMENT OF IRRITABLE BOWEL SYNDROME | |
U467 | USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION | |
U468 | METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS | |
U469 | TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE | |
U47 | STIMULATION OF THE RELEASE OF GROWTH HORMONE | |
U470 | THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION | |
U471 | METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS | |
U472 | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES | |
U473 | TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL | |
U474 | TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTERO BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN | |
U475 | TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY | |
U476 | METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY | |
U477 | METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA | |
U478 | METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERONALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B | |
U479 | METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY | |
U48 | ANALGESIA | |
U480 | CONTRAST AGENT FOR MRI | |
U481 | DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY | |
U482 | METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR | |
U483 | METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND | |
U484 | METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION | |
U485 | METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA) | |
U486 | EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE | |
U487 | METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA) | |
U488 | METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA | |
U489 | EXPECTORANT | |
U49 | SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA | |
U490 | TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE | |
U491 | METHOD OF DELIVERING A DRUG TO THE LUNG | |
U492 | METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID | |
U493 | TREATMENT OF TYPE 2 DIABETES MELLITUS | |
U494 | TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER | |
U495 | PERITONEAL DIALYSIS SOLUTION | |
U496 | METHOD FOR TREATING CHRONIC RENAL FAILURE | |
U497 | RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS | |
U498 | INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST | |
U499 | METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION | |
U5 | METHOD OF PRODUCING BRONCHODILATION | |
U50 | USE IN TREATING INFLAMMATORY DERMATOSES | |
U500 | USE AS AN ANTIHYPERTENSIVE AGENT | |
U501 | TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS | |
U502 | PITYRIASIS VERSICOLOR | |
U503 | GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR | |
U504 | TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS | |
U505 | ULTRASOUND CONTRAST AGENT | |
U506 | PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE,BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE. | |
U507 | ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE | |
U508 | METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS | |
U509 | TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEIOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY | |
U51 | BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING | |
U510 | TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES | |
U511 | USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA | |
U512 | USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA | |
U513 | METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA | |
U514 | PREVENTION OF OVULATION IN A WOMAN | |
U515 | TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY | |
U516 | METHOD OF TREATING A PSYCHOTIC DISEASE | |
U517 | STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS | |
U518 | OBSESSIVE COMPULSIVE DISORDER | |
U519 | POST OPERATIVE NAUSEA AND VOMITING | |
U52 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION | |
U520 | PREMENOPAUSAL OSTEOPOROSIS | |
U521 | METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C | |
U522 | TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA | |
U523 | METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED U524 METHOD OF TREATING DIARRHEA | |
U524 | METHOD OF TREATING DIARRHEA | |
U525 | METHOD OF TREATING PARASITIC INFECTIONS | |
U526 | METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION | |
U527 | METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE | |
U528 | PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING | |
U529 | ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE | |
U53 | HYPERCALCEMIA OF MALIGNANCY | |
U530 | TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES | |
U531 | TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES | |
U532 | TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR | |
U533 | ERECTILE DYSFUNCTION | |
U534 | HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA | |
U535 | TREATMENT OF SOCIAL ANXIETY DISORDER | |
U536 | CONTRAST AGENT FOR MAGNETIC RESONACE IMAGING | |
U537 | TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE | |
U538 | FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS | |
U539 | TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE | |
U54 | REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS | |
U540 | TREATMENT OF FUNGAL INFECTIONS | |
U541 | METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1 | |
U542 | METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION | |
U543 | TREATMENT OF SCHIZOPHRENIA | |
U544 | TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE | |
U545 | METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT | |
U546 | USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE | |
U547 | MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER | |
U548 | A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER | |
U549 | USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER | |
U55 | TREATMENT OF PAIN | |
U550 | TREATMENT OF BIPOLAR MANIA AND SCHIZOPHRENIA | |
U551 | METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID | |
U552 | TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION | |
U553 | MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS | |
U554 | TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS | |
U555 | TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS | |
U556 | USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING | |
U557 | NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS | |
U558 | INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE) | |
U56 | AID TO SMOKING CESSATION | |
U57 | OPHTHALMIC USE OF NORFLOXACIN | |
| 插花造型 | U58 | METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES |
U59 | METHOD OF TREATING HYPERCHOLESTEROLEMIA | |
U6 | METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS [产生拟交感作用的方法] | |
U60 | NASAL ADMINISTRATION OF BUTORPHANOL [布托啡诺的鼻内给药] | |
U61 | CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD | |
U62 | CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY | |
U63 | ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE | |
U64 | TREATMENT OF VIRAL INFECTIONS | |
U65 | METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV [HIV 感染患者的治疗方法] | |
U66 | TRIPHASIC REGIMEN | |
U67 | METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL | |
U68 | TREATMENT OF ACTINIC KERATOSIS | |
U69 | TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS | |
U7 | INCREASING CARDIAC CONTRACTILITY | |
U70 | TREATMENT OF TRANSIENT INSOMNIA | |
U71 | METHOD OF TREATMENT OF HEART FAILURE[心力衰竭的治疗方法] | |
U72 | TREATMENT OF MIGRAINE | |
U73 | METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES | |
U74 | METHOD OF PROVIDING HYPNOTIC EFFECT | |
U75 | RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS | |
U76 | USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM | |
U77 | TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS | |
U78 | ULCERATIVE COLITIS | |
U79 | SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURN DUE TO GERD | |
U8 | ACUTE MYOCARDIAL INFARCTION | |
U80 | METHOD OF TREATING OCULAR BACTERIAL INFECTIONS | |
U81 | RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS | |
U82 | TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE | |
U83 | TREATMENT OF SEIZURES | |
U84 | A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS | |
U85 | NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS | |
U86 | METHOD OF TREATING CERTAIN FORMS OF EPILEPSY | |
U87 | METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS | |
U88 | TREATMENT OF MODERATE PLAQUE PSORIASIS | |
U89 | TREATMENT OR PROPHYLAXIS OF EMESIS [呕吐的预防或治疗] | |
U9 | CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT [癌症化疗伴发呕吐的控制] | |
U90 | TREATMENT OF PSYCHOTIC DISORDERS [精神病的治疗] | |
U91 | ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS | |
U92 | TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATHY | |
U93 | USE AS AN ANTIHISTAMINE/ DECONGESTANT | |
U94 | TREATMENT OF ADULTS WITH ADVANCED HIV INFECTION WHO ARE INTOLERANT OF APPROVED THERAPIES WITH PROVEN CLINICAL BENEFIT OR WHO HAVE EXPERIENCED SIGNIFICANT CLINICAL OR IMMUNOLOGIC DETERIORATION WHILE RECEIVING THESE THERAPIES OR FOR WHOM SUCH THERAPIES ARE CONTRAINDICATED | |
U95 | SHORT TERM MANAGEMENT OF MODERATE PRURITUS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS | |
U96 | METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS | |
U97 | A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT | |
U98 | A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL | |
U99 | METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM | |
本文发布于:2023-07-02 08:56:09，感谢您对本站的认可！
本文链接：https://www.wtabcd.cn/fanwen/fan/89/1064341.html
版权声明：本站内容均来自互联网，仅供演示用，请勿用于商业和其他非法用途。如果侵犯了您的权益请与我们联系，我们将在24小时内删除。
| 留言与评论（共有 0 条评论） |
